Effects of dextran sulphate on lymphoblast extravasation into inflammatory skin sites.
The effects of high molecular weight dextran sulphate (DXS) on the migration of 125I-labelled deoxyuridine-labelled peripheral lymphoblasts (stimulated by oxazolone) were studied in vivo by injecting the drug (50 mg/kg) subcutaneously in recipients, and by following the fate of oxazolone-stimulated peripheral lymphocytes treated in vitro with DXS in non-treated syngeneic recipients. Both types of experiments demonstrate that DXS considerably reduces lymphoblast extravasation in skin sites inflamed either by non-immune causes or by DTH. Our results also demonstrate that oxazolone-stimulated peripheral lymphocytes, after in vitro treatment with DXS, are unable to transfer antigen-specific contact hypersensitivity to unsensitized recipients. The results obtained suggest that the drug acts on both T effector cells and lymphoblasts.
D000818:Animals; D002465:Cell Movement / Q000187:drug effects; D003872:Dermatitis / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D016264:Dextran Sulfate; D003911:Dextrans / Q000494:pharmacology*; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006968:Hypersensitivity, Delayed; D007116:Immunization, Passive; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010081:Oxazolone / Q000276:immunology
D003911:Dextrans; D010081:Oxazolone; D016264:Dextran Sulfate